Amalgamated Bank grew its position in Colgate-Palmolive (NYSE:CL) by 0.7% during the 1st quarter, HoldingsChannel.com reports. The fund owned 110,439 shares of the company’s stock after purchasing an additional 806 shares during the period. Amalgamated Bank’s holdings in Colgate-Palmolive were worth $7,916,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently made changes to their positions in CL. Elkhorn Investments LLC raised its position in shares of Colgate-Palmolive by 4.5% in the 4th quarter. Elkhorn Investments LLC now owns 17,429 shares of the company’s stock valued at $1,246,000 after purchasing an additional 743 shares during the last quarter. CHICAGO TRUST Co NA raised its position in shares of Colgate-Palmolive by 24.5% in the 1st quarter. CHICAGO TRUST Co NA now owns 4,114 shares of the company’s stock valued at $295,000 after purchasing an additional 810 shares during the last quarter. Salem Investment Counselors Inc. raised its position in shares of Colgate-Palmolive by 0.8% in the 4th quarter. Salem Investment Counselors Inc. now owns 101,315 shares of the company’s stock valued at $7,644,000 after purchasing an additional 820 shares during the last quarter. Global X Management Co. LLC raised its position in shares of Colgate-Palmolive by 7.2% in the 1st quarter. Global X Management Co. LLC now owns 12,371 shares of the company’s stock valued at $887,000 after purchasing an additional 829 shares during the last quarter. Finally, Bank of The Ozarks raised its position in shares of Colgate-Palmolive by 5.9% in the 1st quarter. Bank of The Ozarks now owns 15,171 shares of the company’s stock valued at $1,087,000 after purchasing an additional 841 shares during the last quarter. 73.07% of the stock is currently owned by institutional investors and hedge funds.
Several brokerages recently commented on CL. Barclays set a $75.00 price objective on shares of Colgate-Palmolive and gave the company a “hold” rating in a research report on Thursday, March 15th. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $72.00 price objective on shares of Colgate-Palmolive in a research report on Thursday, May 24th. Argus raised shares of Colgate-Palmolive from a “hold” rating to a “buy” rating in a research report on Friday, May 25th. They noted that the move was a valuation call. Stifel Nicolaus reaffirmed a “hold” rating and issued a $75.00 price objective on shares of Colgate-Palmolive in a research report on Wednesday, April 18th. Finally, Zacks Investment Research raised shares of Colgate-Palmolive from a “sell” rating to a “hold” rating in a research report on Tuesday, April 17th. Four analysts have rated the stock with a sell rating, eleven have given a hold rating and three have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $76.08.
In other news, insider Daniel B. Marsili sold 19,500 shares of the firm’s stock in a transaction that occurred on Friday, June 15th. The shares were sold at an average price of $63.25, for a total transaction of $1,233,375.00. Following the sale, the insider now owns 78,065 shares of the company’s stock, valued at approximately $4,937,611.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Vice Chairman Franck J. Moison sold 80,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 15th. The stock was sold at an average price of $61.75, for a total transaction of $4,940,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 161,579 shares of company stock valued at $10,215,058 over the last three months. 1.02% of the stock is currently owned by insiders.
Colgate-Palmolive opened at $63.90 on Thursday, according to Marketbeat Ratings. Colgate-Palmolive has a 12-month low of $61.28 and a 12-month high of $77.91. The company has a quick ratio of 0.75, a current ratio of 1.08 and a debt-to-equity ratio of 64.85. The company has a market cap of $55.23 billion, a price-to-earnings ratio of 22.26, a price-to-earnings-growth ratio of 2.56 and a beta of 0.75.
Colgate-Palmolive (NYSE:CL) last posted its quarterly earnings results on Friday, April 27th. The company reported $0.74 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.01. Colgate-Palmolive had a net margin of 13.30% and a return on equity of 1,486.69%. The company had revenue of $4 billion during the quarter, compared to analyst estimates of $4.01 billion. During the same period last year, the firm posted $0.67 EPS. Colgate-Palmolive’s revenue for the quarter was up 6.4% compared to the same quarter last year. analysts expect that Colgate-Palmolive will post 3.14 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, August 15th. Shareholders of record on Wednesday, July 18th will be given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 2.63%. The ex-dividend date of this dividend is Tuesday, July 17th. Colgate-Palmolive’s dividend payout ratio is presently 58.54%.
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. It operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The company offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals; personal care products comprising bar and liquid hand soaps, shower gels, shampoos, conditioners, and deodorants and antiperspirants; and home care products, such as laundry and dishwashing detergents, fabric conditioners, household cleaners, and other related products.
Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive (NYSE:CL).
Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.